SM 88

Drug Profile

SM 88

Alternative Names: SM88

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tyme Technologies
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Free radical stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer
  • Phase I Cancer
  • Preclinical Osteosarcoma

Most Recent Events

  • 06 Nov 2017 Efficacy and adverse events data from a phase I trial in Cancer released by Tyme Technologies
  • 26 Oct 2017 Updated interim efficacy data from a phase I trial in Cancer released by Tyme Technologies
  • 25 Oct 2017 Preclinical trials in Osteosarcoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top